| Field | Specification |
|---|---|
| Target | |
| Alternative names | L dopachrome tautomerase; DCT; Dopachrome delta isomerase; Dopachrome tautomerase; Dopachrome tautomerase dopachrome delta isomerase; tyrosine related protein 2; DT; EC 5.3.3.12; L dopachrome Delta isomerase; L-dopachrome Delta-isomerase; L-dopachrome tautomerase; TRP 2; TRP-2; TRP2; Tyrosinase related protein 2; Tyrosinase-related protein 2; TYRP2; TYRP2_HUMAN |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Recombinant Human L-dopachrome tautomerase protein (44-205AA) |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This polyclonal anti-DCT antibody raised in Rabbit, conjugated with Biotin, tested in ELISA. Designed to detect DCT in Human for cell biology research.
Key elements and design rationale
- Immunogen: Recombinant Human L-dopachrome tautomerase protein (44-205AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
- Biotin: Streptavidin/avidin amplification; block endogenous biotin in biotin-rich samples.
Biological background
DCT (also: L dopachrome tautomerase, DCT, Dopachrome delta isomerase, Dopachrome tautomerase, Dopachrome tautomerase dopachrome delta isomerase, tyrosine related protein 2, DT, EC 5.3.3.12, L dopachrome Delta isomerase, L-dopachrome Delta-isomerase, L-dopachrome tautomerase, TRP 2, TRP-2, TRP2, Tyrosinase related protein 2, Tyrosinase-related protein 2, TYRP2, TYRP2_HUMAN) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current DCT annotation relevant to cell biology.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
DCT is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects DCT in ELISA applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Biotin: streptavidin/avidin amplification. Block endogenous biotin in biotin-rich samples.
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing DCT; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
